| Year |
Citation |
Score |
| 2014 |
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs G, Peer CJ, Petros WP. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 73: 991-7. PMID 24619498 DOI: 10.1007/S00280-014-2432-X |
0.421 |
|
| 2012 |
Peer CJ, Younis IR, Leonard SS, Gannett PM, Minarchick VC, Kenyon AJ, Rojanasakul Y, Callery PS. Glutathione conjugation of busulfan produces a hydroxyl radical-trapping dehydroalanine metabolite. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 1170-7. PMID 22725664 DOI: 10.3109/00498254.2012.696740 |
0.676 |
|
| 2009 |
Younis IR, Stamatakis MK, Callery PS, Meyer-Stout PJ. Influence of pH on the dissolution of folic acid supplements. International Journal of Pharmaceutics. 367: 97-102. PMID 18929632 DOI: 10.1016/J.Ijpharm.2008.09.028 |
0.552 |
|
| 2008 |
Younis IR, Elliott M, Peer CJ, Cooper AJ, Pinto JT, Konat GW, Kraszpulski M, Petros WP, Callery PS. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. The Journal of Pharmacology and Experimental Therapeutics. 327: 770-6. PMID 18791061 DOI: 10.1124/Jpet.108.142208 |
0.703 |
|
| 2008 |
Cooper AJ, Younis IR, Niatsetskaya ZV, Krasnikov BF, Pinto JT, Petros WP, Callery PS. Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1546-52. PMID 18474673 DOI: 10.1124/Dmd.108.020768 |
0.653 |
|
| 2007 |
Peer CJ, Shakleya DM, Younis IR, Kraner JC, Callery PS. Direct-injection mass spectrometric method for the rapid identification of fentanyl and norfentanyl in postmortem urine of six drug-overdose cases. Journal of Analytical Toxicology. 31: 515-21. PMID 17988466 DOI: 10.1093/Jat/31.8.515 |
0.601 |
|
| 2006 |
Sanga M, Younis IR, Tirumalai PS, Bland TM, Banaszewska M, Konat GW, Tracy TS, Gannett PM, Callery PS. Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation. Toxicology and Applied Pharmacology. 211: 148-56. PMID 16038959 DOI: 10.1016/J.Taap.2005.06.017 |
0.423 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2009 |
Younis IR, Malone S, Friedman HS, Schaaf LJ, Petros WP. Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemotherapy and Pharmacology. 63: 517-24. PMID 18496691 DOI: 10.1007/S00280-008-0769-8 |
0.271 |
|
| 2018 |
Volpe DA, Xu Y, Sahajwalla CG, Younis IR, Patel V. Methadone Metabolism And Drug-Drug Interactions: In Vitro And In Vivo Literature Review. Journal of Pharmaceutical Sciences. PMID 30205091 DOI: 10.1016/j.xphs.2018.08.025 |
0.267 |
|
| 2019 |
Younis IR, Lakota EA, Volpe DA, Patel V, Xu Y, Sahajwalla CG. Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned. Journal of Clinical Pharmacology. PMID 30973652 DOI: 10.1002/jcph.1405 |
0.22 |
|
| 2008 |
Rao AV, Younis IR, Sand GJ, Spasojevic I, Adams DJ, Decastro CM, Gockerman JP, Peterson BL, Petros WP, Moore JO, Rizzieri DA. Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma. 49: 1523-9. PMID 18766965 DOI: 10.1080/10428190802210700 |
0.22 |
|
| 2018 |
Talal AH, Venuto CS, Younis I. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. Clinical Pharmacology in Drug Development. 6: 206-212. PMID 28263464 DOI: 10.1002/cpdd.336 |
0.212 |
|
| 2022 |
Ravenstijn P, Chetty M, Manchandani P, Elmeliegy M, Qosa H, Younis I. Design and conduct considerations for studies in patients with hepatic impairment. Clinical and Translational Science. PMID 36176049 DOI: 10.1111/cts.13428 |
0.198 |
|
| 2024 |
Younis IR, Nelson C, Weber EJ, Qin AR, Watkins TR, Othman AA. Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. Journal of Clinical Pharmacology. PMID 38520128 DOI: 10.1002/jcph.2427 |
0.165 |
|
| 2023 |
Weber E, Younis I, Nelson C, Ding D, Qin A, Xiao D, Watkins TR, Othman AA. Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Journal of Clinical Pharmacology. PMID 36700458 DOI: 10.1002/jcph.2206 |
0.158 |
|
| 2022 |
Shugg T, Powell NR, Marroum PJ, Skaar TC, Younis IR. Evaluation of U.S. food and drug administration drug label recommendations for co-administration of antivirals and acid reducing agents. Clinical Pharmacology and Therapeutics. PMID 35920069 DOI: 10.1002/cpt.2723 |
0.145 |
|
| 2012 |
Petros WP, Younis IR, Ford JN, Weed SA. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy. 32: 920-31. PMID 23033231 DOI: 10.1002/J.1875-9114.2012.01117 |
0.128 |
|
| 2022 |
Qosa H, Hassan HE, Younis IR. Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases. Journal of Clinical Pharmacology. S72-S78. PMID 36461747 DOI: 10.1002/jcph.2167 |
0.12 |
|
| 2023 |
Younis IR, Hsueh CH, Nelson C, Billin AN, Yue MS, Xiao D, Watkins TR, Othman AA. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Journal of Clinical Pharmacology. PMID 37128693 DOI: 10.1002/jcph.2260 |
0.119 |
|
| 2013 |
Younis IR, Rogers H, Zhang H, Zhu H, Uppoor RS, Mehta MU. An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: review of recent cases in psychiatry drugs. Journal of Clinical Pharmacology. 53: 1005-9. PMID 23842865 DOI: 10.1002/jcph.118 |
0.107 |
|
| 2023 |
Younis I, Weber E, Nelson C, Kirby BJ, Shen G, Xiao D, Watkins TR, Othman AA. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Clinical Pharmacokinetics. PMID 36906733 DOI: 10.1007/s40262-023-01214-w |
0.101 |
|
| 2022 |
Younis IR, Kirby BJ, Billin AN, Xiao D, Song Q, Watkins T, Othman AA. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Cilofexor, a Novel Nonsteroidal Farnesoid X Receptor Agonist, in Healthy Volunteers. Clinical and Translational Science. PMID 36573450 DOI: 10.1111/cts.13469 |
0.101 |
|
| 2023 |
Mitra A, Ahmed MA, Krishna R, Sun K, Gibbons FD, Campagne O, Rayad N, Roman YM, Albusaysi S, Burian M, Younis I. Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-based Gene Therapy Product Development - A White Paper. Clinical Pharmacology and Therapeutics. PMID 37313953 DOI: 10.1002/cpt.2972 |
0.097 |
|
| 2023 |
Zhu R, Vora B, Menon S, Younis I, Dwivedi G, Meng Z, Datta-Mannan A, Manchandani P, Nayak S, Tammara BK, Garhyan P, Iqbal S, Dagenais S, Chanu P, Mukherjee A, et al. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval- An Industry Perspective. Clinical Pharmacology and Therapeutics. PMID 37393555 DOI: 10.1002/cpt.2988 |
0.093 |
|
| 2018 |
Sampson MR, Cao KY, Gish PL, Hyon K, Mishra P, Tauber W, Zhao P, Zhou EH, Younis IR. Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors. Journal of Clinical Pharmacology. PMID 30452774 DOI: 10.1002/jcph.1345 |
0.093 |
|
| 2016 |
Ayala RC, Arya V, Younis IR. Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives. Journal of Clinical Pharmacology. 56: 541-7. PMID 26384089 DOI: 10.1002/Jcph.637 |
0.09 |
|
| 2015 |
Momper JD, Chang Y, Jackson M, Schuette P, Seo S, Younis I, Abernethy DR, Yao L, Capparelli EV, Burckart GJ. Adverse Event Detection and Labeling in Pediatric Drug Development: Antiretroviral Drugs. Therapeutic Innovation & Regulatory Science. 49: 302-309. PMID 30222418 DOI: 10.1177/2168479014565471 |
0.089 |
|
| 2017 |
Younis I, Ahmed MA, Burman KD, Soldin OP, Jonklaas J. Stable isotope pharmacokinetic studies provide insight into effects of age, sex, and weight on levothyroxine metabolism. Thyroid : Official Journal of the American Thyroid Association. PMID 29212434 DOI: 10.1089/thy.2017.0380 |
0.084 |
|
| 2024 |
Weber EJ, Younis IR, Wang L, Xiao D, Barchuk WT, Othman AA. Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist. Clinical Pharmacology in Drug Development. PMID 38346861 DOI: 10.1002/cpdd.1384 |
0.082 |
|
| 2022 |
Moore KT, Fossler MJ, Younis I. The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials. Journal of Clinical Pharmacology. PMID 36031876 DOI: 10.1002/jcph.2135 |
0.082 |
|
| 2011 |
Soldin OP, Soldin SJ, Vinks AA, Younis I, Landy HJ. Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope study. Therapeutic Drug Monitoring. 32: 767-73. PMID 20962709 DOI: 10.1097/FTD.0b013e3181f12fe5 |
0.075 |
|
| 2022 |
Younis IR, Manchandani P, Hassan HE, Qosa H. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade. Clinical Pharmacology and Therapeutics. PMID 35780478 DOI: 10.1002/cpt.2701 |
0.07 |
|
| 2020 |
Kalaria SN, Farchione TR, Mathis MV, Gopalakrishnan M, Younis I, Uppoor R, Mehta M, Wang Y, Zhu H. Assessment of Similarity in Antipsychotic Exposure-Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. Journal of Clinical Pharmacology. PMID 31994186 DOI: 10.1002/jcph.1580 |
0.065 |
|
| 2024 |
Younis IR, Wang F, Othman AA. Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment Studies. Journal of Clinical Pharmacology. PMID 38346862 DOI: 10.1002/jcph.2410 |
0.063 |
|
| 2023 |
Avachat C, Younis IR, Birnbaum AK. Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation. Clinical Pharmacology and Therapeutics. PMID 37750407 DOI: 10.1002/cpt.3059 |
0.062 |
|
| 2021 |
Ahmed MA, Kalaria SN, Younis IR. Concordance of Exposure Changes Due to Renal Impairment between Results of Dedicated Renal Impairment Studies and Population PK Predictions. Journal of Clinical Pharmacology. PMID 33997992 DOI: 10.1002/jcph.1907 |
0.061 |
|
| 2016 |
Younis IR, Powell JR, Rostami-Hodjegan A, Corrigan B, Stockbridge N, Sinha V, Zhao P, Jadhav P, Flamion B, Cook J. Utility of Model Based Approaches for Informing Dosing Recommendations in Specific Populations: Report from the Public AAPS Workshop. Journal of Clinical Pharmacology. PMID 27365151 DOI: 10.1002/jcph.787 |
0.06 |
|
| 2020 |
Pai SM, Othman AA, Rusch L, Masters JC, Greene D, Rogge M, Gries JM, Clementi W, Kumar P, Younis I, Salem AH, Gaynes B, Pastino G, Derendorf H. Science and Evidence-based Review and Approval of COVID-19 Vaccines: A Statement of Support for the U.S. FDA. Journal of Clinical Pharmacology. PMID 33274473 DOI: 10.1002/jcph.1794 |
0.059 |
|
| 2020 |
Gopalakrishnan M, Zhu H, Farchione TR, Mathis M, Mehta M, Uppoor R, Younis I. The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration. The Journal of Clinical Psychiatry. 81. PMID 32141721 DOI: 10.4088/JCP.19r12960 |
0.057 |
|
| 2018 |
Hodowanec AC, Pikis A, Komatsu TE, Sampson MR, Younis IR, O'Rear JJ, Singer ME. Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives. Journal of Clinical Pharmacology. PMID 30586161 DOI: 10.1002/jcph.1363 |
0.057 |
|
| 2020 |
Gopalakrishnan M, Farchione T, Mathis M, Zhu H, Mehta M, Uppoor R, Younis I. Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration. Psychiatric Research and Clinical Practice. 3: 38-45. PMID 36101554 DOI: 10.1176/appi.prcp.20200003 |
0.052 |
|
| 2021 |
Sharma A, Sahasrabudhe V, Musib L, Zhang S, Younis I, Kanodia J. Time to rethink the current paradigm for assessing kidney function in drug development and beyond. Clinical Pharmacology and Therapeutics. PMID 34800044 DOI: 10.1002/cpt.2489 |
0.052 |
|
| 2011 |
Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, et al. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemotherapy and Pharmacology. 67: 465-74. PMID 21079958 DOI: 10.1007/S00280-010-1507-6 |
0.042 |
|
| 2019 |
Kalaria SN, Zhu H, Farchione TR, Mathis MV, Gopalakrishnan M, Uppoor R, Mehta M, Younis I. A Quantitative Justification of Similarity in Placebo Response between Adults and Adolescents with Acute Exacerbation of Schizophrenia in Clinical Trials. Clinical Pharmacology and Therapeutics. PMID 31069784 DOI: 10.1002/cpt.1501 |
0.041 |
|
| 2013 |
Younis IR, Laughren TP, Wang Y, Mathis M, Gobburu JV. An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia. Journal of Clinical Psychopharmacology. 33: 152-6. PMID 23422374 DOI: 10.1097/JCP.0b013e31828393a8 |
0.04 |
|
| 2024 |
Cespedes MS, Das M, Yager J, Prins M, Krznaric I, de Jong J, Xiao D, Shao Y, Wong P, Kintu A, Carter C, Hoornenborg E, Ruane P, Phoenix J, Younis I, et al. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial. Transgender Health. 9: 46-52. PMID 38312459 DOI: 10.1089/trgh.2022.0048 |
0.021 |
|
| 2020 |
Younis IR, Gopalakrishnan M, Mathis M, Mehta M, Uppoor R, Zhu H, Farchione T. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications. Jama Psychiatry. PMID 32609294 DOI: 10.1001/jamapsychiatry.2020.1596 |
0.01 |
|
| Hide low-probability matches. |